Sibannac Inc. (OTC:SNNC) Stock Falls After Distribution and Formulation Updates

If you are currently looking into companies that could come into focus among investors this morning, then you could consider taking a look at Sibannac Inc. (OTC:SNNC). On Tuesday, the company entered the news cycle after it announced that it had inked a worldwide distribution agreement with Direct Global Supply, the alternative health and supplement manufacturer.

As per the terms of the agreement, Direct Global Supply would place Sibannac’s NOHO After Shot product with retailers and wholesalers. It was revealed that Direct Global had been successful in placing the NOHO After Shot product with a national-level distributor. The new release noted that the distributor was involved in testing the product at its 40 corporate-owned outlets to figure out sell-through and evaluation metrics. Sibannac would incorporate the feedback from the exercise and other relationships in order to improve its graphic updates, packaging, and profiles of flavors.

It was also announced yesterday that Direct Global and Sibannac had also become involved in a collaboration focused on the development of new Kratom products that would be manufactured at the company’s plant located in Scottsdale, Arizona. The products would all be sold online and directly to consumers through the strong wholesale distribution network operated by Direct Global. The products would also be made available at The Kevern, the first retail location of Sibannac, which would open in a few weeks.

However, that was not all. It also emerged yesterday that Sibannac was also involved in working with two other sales and distribution partners. Those partners are specialists in sales at big-box stores and trucking outlets. One of those relationships already bore fruit for the company since it introduced the NOHO After Shot product to a convenience store chain with a nationwide presence. The convenience store chain was considering the product to be included in its line of emerging brands.

Ian Leigh

Ian Leigh is a specialist in analyzing stocks, SEC and OTC filings, and financials of public and privately-held companies. He has played a significant role in M&A activity, consulting with publicly-held firms on acquisitions and divestitures. He also consults on valuations and branding. He lectures at major universities and teaches at specialty financial schools.